SCHEMBL1633970

SCHEMBL1633970

Nc1cccc(S(F)(F)(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
CASP1 P29466 1/20 0.52
RECQL P46063 1/20 0.52
KDM1A O60341 1/20 0.46
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 5/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA7 P43166 1/20 0.42
MAOA P21397 3/20 0.41
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ENPP2 Q13822 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29643291 1.00 CYP3A4 (0.52) CYP3A4CASP1RECQLKDM1ATSHR
SCHEMBL12024595 0.81 CYP3A4 (0.48) CYP3A4CASP1RECQLTSHRMAPK1
SCHEMBL1966415 0.81 KDM1A (0.48) KDM1AAKR1C3AKR1C2
SCHEMBL19680105 0.75 AKR1C3 (0.50) CYP3A4KDM1AALDH1A1TDP1LMNA
SCHEMBL816745 0.73 PDE2A (0.37) CYP3A4TSHRALDH1A1MAPTGAA
SCHEMBL9312777 0.73 PDE2A (0.37) CYP3A4CASP1RECQLTSHRALDH1A1
SCHEMBL15108851 0.72 ACHE (0.44) CYP3A4KDM1AMAPK1AKR1C3AKR1C2
SCHEMBL11661863 0.71 CYP3A4 (1.00) CYP3A4CASP1RECQLTSHRMAPK1
SCHEMBL1934399 0.71 CYP3A4 (1.00) CYP3A4CASP1RECQLTSHRMAPK1
SCHEMBL16054 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601235-B1 BICYCLIC HETEROARYL DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF XWPHARMA LTD (KY) 2026-03-04 EP disclosed
WO-2025108234-A1 COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 四川科伦药物研究院有限公司 2025-05-30 WO disclosed
EP-3635022-B1 METHODS FOR MAKING FUNCTIONALIZED FLUORINATED MONOMERS, FLUORINATED MONOMERS, AND COMPOSITIONS FOR MAKING THE SAME ETNA TEC LTD (US) 2025-05-21 EP disclosed
WO-2025051180-A1 LACTAM DERIVATIVE AND USE THEREOF 上海超阳药业有限公司 2025-03-13 WO disclosed
US-12239655-B2 Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents EMORY UNIVERSITY (US) 2025-03-04 US disclosed
CN-118359634-A Pyrazole derivative and medical use thereof 正大天晴药业集团股份有限公司 2024-07-19 CN disclosed
EP-4389738-A1 SOS1 INHIBITOR AND USE THEREOF Kanaph Therapeutics Inc. (KR) 2024-06-26 EP disclosed
US-20240199583-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS ACHILLION PHARMACEUTICALS, INC. 2024-06-20 US disclosed
WO-2024121013-A1 SULFONYL DERIVATIVES AS CCR6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-06-13 WO disclosed
US-11926617-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2024-03-12 US disclosed
WO-2007031265-A2 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER NOVARTIS AG (CH) 2007-03-22 WO disclosed
WO-2006108700-A1 3-TRIAZOLYLTHIOALKYL-3-AZABICYCLO (3 - 1 - O) HEXANES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2006-10-19 WO disclosed
EP-1658266-A1 PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS Sanofi-Aventis Deutschland GmbH (DE) 2006-05-24 EP disclosed
US-20050148652-A1 Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-07-07 US disclosed
WO-2005021492-A1 PENTAFLUOROSULFANYL PHENYL-SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS MEDICAMENTS OR DIAGNOSTIC AGENTS AND MEDICAMENT CONTAINING SAID COMPOUNDS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-03-10 WO disclosed
US-20050043401-A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-24 US disclosed
EP-0672038-B1 HERBICIDES ZENECA LTD (GB) 2000-01-19 EP disclosed
US-5856273-A CONTROLLING WEEDS ZENECA LIMITED (GB) 1999-01-05 US disclosed
EP-0672038-A1 HERBICIDES ZENECA LIMITED (GB) 1995-09-20 EP disclosed
WO-1994013652-A1 HERBICIDES ZENECA LIMITED (GB) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148652-A1 Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates PFAS, DDT, PNPO CYP3A4 29/4885CASP1 959/4885RECQL 1893/4885
US-20050043401-A1 Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them TNNI3, TNNT2, RYR2 CYP3A4 1286/4885CASP1 588/4885RECQL 268/4885
US-12239655-B2 Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents NOX1, NOX3, NOX4 CYP3A4 1105/4885CASP1 832/4885RECQL 3212/4885
US-20240199583-A1 ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS CFD, TFPI, CFH CYP3A4 617/4885CASP1 160/4885RECQL 1785/4885
US-11926617-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH CYP3A4 617/4885CASP1 160/4885RECQL 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.